A review of amphetamine extended release once-daily options for the management of attention-deficit hyperactivity disorder
- PMID: 38391788
- DOI: 10.1080/14737175.2024.2321921
A review of amphetamine extended release once-daily options for the management of attention-deficit hyperactivity disorder
Abstract
Introduction: Amphetamine preparations are one of the two categories of stimulant medications approved for the treatment of attention deficit hyperactivity disorder (ADHD). Optimal treatment of ADHD aims to reduce core symptoms for as much of the waking hours as possible, leading to longer-acting delivery formats. In addition, the pediatric population commonly has difficulty swallowing pills and manufacturers have developed a variety of options to facilitate this concern. These include chewable tablets, capsules that may be sprinkled on soft food, liquids and transdermal patches.
Areas covered: This article reviews the once-daily extended-release preparations currently available for amphetamine compounds, their pharmacodynamics, and common adverse effects.
Expert opinion: There is an extensive evidence base supporting use of amphetamine preparations in the treatment of ADHD. Rapid onset of action and a favorable side effect profile make these widely used. The availability of once-daily extended-release chewable tablets, capsules that can be opened and sprinkled, and liquid formulations provides clinicians with multiple options to meet the specific needs of patients with difficulty swallowing whole pills.
Keywords: ADHD; Amphetamine; delivery; dextroamphetamine; extended-release; once-daily treatment.
Similar articles
-
Methylphenidate and dexmethylphenidate formulations for children with attention-deficit/hyperactivity disorder.Am J Health Syst Pharm. 2014 Jul 15;71(14):1163-70. doi: 10.2146/ajhp130638. Am J Health Syst Pharm. 2014. PMID: 24973373 Review.
-
New Formulations of Stimulants: An Update for Clinicians.J Child Adolesc Psychopharmacol. 2019 Jun;29(5):324-339. doi: 10.1089/cap.2019.0043. Epub 2019 Apr 30. J Child Adolesc Psychopharmacol. 2019. PMID: 31038360 Free PMC article. Review.
-
Pediatric attention deficit hyperactivity disorder (ADHD): 2022 updates on pharmacological management.Expert Rev Clin Pharmacol. 2023 Jul-Dec;16(9):799-812. doi: 10.1080/17512433.2023.2249414. Epub 2023 Aug 22. Expert Rev Clin Pharmacol. 2023. PMID: 37587841 Review.
-
QuilliChew extended-release chewable tablets for the treatment of ADHD in patients ages 6 years old and above.Expert Opin Drug Deliv. 2018 Dec;15(12):1263-1270. doi: 10.1080/17425247.2018.1545759. Epub 2018 Nov 15. Expert Opin Drug Deliv. 2018. PMID: 30404549
-
A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).Pediatrics. 2004 Mar;113(3 Pt 1):e206-16. doi: 10.1542/peds.113.3.e206. Pediatrics. 2004. PMID: 14993578 Clinical Trial.
Cited by
-
Valerenic acid ameliorates amphetamine-related neurotoxicity by improving hypothalamus tyrosine hydroxylase and histamine-N-methyl transferase enzymes.Toxicol Rep. 2025 Jan 29;14:101936. doi: 10.1016/j.toxrep.2025.101936. eCollection 2025 Jun. Toxicol Rep. 2025. PMID: 39980660 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
